Literature DB >> 15948257

Alpha-catenin expression is decreased in patients with gastric carcinoma.

Yong-Ning Zhou1, Cai-Pu Xu, Yu Chen, Biao Han, Shi-Ming Yang, Dian-Chun Fang.   

Abstract

AIM: To assess the expression of alpha-catenin in gastric carcinoma and to determine the role of alpha-catenin expression in gastric carcinogenesis.
METHODS: alpha-catenin expression was assessed by semi-quantitative reverse transcriptase-polymerase chain reaction and immunohistochemical staining in 49 gastric carcinomas, 26 adjacent non-cancerous mucosae, and gastric biopsy specimens from 11 healthy controls.
RESULTS: mRNA levels of alpha-catenin were reduced or absent in 34 of 49 (69%) gastric carcinoma tissues and in 5 of 26 (19%) tumor-free gastric mucosae of carcinoma patients, respectively. Of the carcinoma samples with altered alpha-catenin mRNA levels, alpha-catenin expression was negative in 20 and decreased in 14 cases. Up to 69% of tumors were stained abnormally for alpha-catenin. Of the 34 cases whose mRNA expression of alpha-catenin was reduced, 32 (94%) showed abnormal immunostaining patterns, while only 2 showed a normal alpha-catenin expression. The frequency of reduced expression of alpha-catenin mRNA was 14% in well-differentiated carcinomas, higher than that in poorly differentiated carcinomas (86%). A significant correlation was not shown between alpha-catenin expression and both depth of invasion and lymph node metastasis. Moreover, there was no statistical difference between loss or down-regulation of alpha-catenin mRNA and Helicobacter pylori (H. pylori) infection.
CONCLUSION: Downregulation of alpha-catenin expression is common in gastric carcinoma, and alpha-catenin expression may be used as a differentiation marker. Downregulation of alpha-catenin expression may be an early event in tumorigenesis. Reduced alpha-catenin expression is not correlated with H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948257      PMCID: PMC4316006          DOI: 10.3748/wjg.v11.i22.3468

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  Regulation of embryonic cell adhesion by the cadherin cytoplasmic domain.

Authors:  C Kintner
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

2.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

3.  Survival in stomach cancer is improving: results of a nationwide population-based Swedish study.

Authors:  L E Hansson; P Sparén; O Nyrén
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

Review 4.  The importance of the E-cadherin-catenin complex in the maintenance of intestinal epithelial homoeostasis: more than intercellular glue?

Authors:  A Jawhari; M Farthing; M Pignatelli
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

5.  Loss of E-cadherin expression in early gastric cancer.

Authors:  P Blok; M E Craanen; W Dekker; G N Tytgat
Journal:  Histopathology       Date:  1999-05       Impact factor: 5.087

6.  E-cadherin germline mutations in familial gastric cancer.

Authors:  P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

7.  alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives.

Authors:  J Yu; M P Ebert; S Miehlke; H Rost; U Lendeckel; A Leodolter; M Stolte; E Bayerdörffer; P Malfertheiner
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

8.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.

Authors:  K F Becker; M J Atkinson; U Reich; I Becker; H Nekarda; J R Siewert; H Höfler
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

Review 9.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 10.  E-cadherin mediated adhesion system in cancer cells.

Authors:  H Shiozaki; H Oka; M Inoue; S Tamura; M Monden
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

View more
  5 in total

1.  Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Authors:  Ying Ye; Michael A McDevitt; Mingzhou Guo; Wei Zhang; Oliver Galm; Steven D Gore; Judith E Karp; Jaroslaw P Maciejewski; Jeanne Kowalski; Hua-Ling Tsai; Lukasz P Gondek; Hsing-Chen Tsai; Xiaofei Wang; Craig Hooker; B Douglas Smith; Hetty E Carraway; James G Herman
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

Review 2.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

3.  Downregulated pseudogene CTNNAP1 promote tumor growth in human cancer by downregulating its cognate gene CTNNA1 expression.

Authors:  Xiangjian Chen; Hua Zhu; Xiaoli Wu; Xuemeng Xie; Guanli Huang; Xiaoqun Xu; Shi Li; Chungen Xing
Journal:  Oncotarget       Date:  2016-08-23

4.  LINC00483 Has a Potential Tumor-Suppressor Role in Colorectal Cancer Through Multiple Molecular Axes.

Authors:  Duilia Brex; Cristina Barbagallo; Federica Mirabella; Angela Caponnetto; Rosalia Battaglia; Davide Barbagallo; Rosario Caltabiano; Giuseppe Broggi; Lorenzo Memeo; Cinzia Di Pietro; Michele Purrello; Marco Ragusa
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

5.  Effect of ghost pepper on cell proliferation, apoptosis, senescence and global proteomic profile in human renal adenocarcinoma cells.

Authors:  Venu Perla; Marjan Nadimi; Rishi Reddy; Gerald R Hankins; Padma Nimmakayala; Robert T Harris; Jagan Valluri; Cristian Sirbu; Umesh K Reddy
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.